Abstract
Postprandial dysmetabolism is a postprandial state characterized by abnormal metabolism of glucose and lipids and, more specifically, of elevated levels of glucose and triglyceride (TG) containing lipoproteins. Since there is evidence that postprandial dysmetabolism is associated with increased cardiovascular mortality and morbidity, due to macro- and microvascular complications, as well as with conditions such as polycystic ovary syndrome (PCOS) and non-alcoholic fatty liver disease (NAFLD), it is recommended that clinicians be alert for early detection and management of this condition. Management consists of a holistic approach including dietary modification, exercise and use of hypoglycemic and hypolipidemic medication aiming to decrease the postprandial values of circulating glucose and triglycerides. This review aims to explain glucose and lipid homeostasis and the impact of postprandial dysmetabolism on the cardiovascular system as well as to offer suggestions with regard to the therapeutic approach for this entity. However, more trials are required to prevent or reverse early and not too late the actual tissue damage due to postprandial dysmetabolism.
Article PDF
Similar content being viewed by others
Avoid common mistakes on your manuscript.
References
O’Keefe JH, Bell DS, 2007 Postprandial hyperglycemia/hyperlipidemia (postprandial dysmetabolism) is a cardiovascular risk factor. Am J Cardiol 100: 899–904.
Aron Off SL, Berkowitz K, Shreiner B, Want L, 2004 Glucose Metabolism and Regulation: Beyond Insulin and Glucagon. Diabetes spectrum 17: 183–190.
Grodsky GM, 1972 A threshold distribution hypothesis for packet storage of insulin and its mathematical modeling. J Clin Invest 51: 2047–2059.
Kahn SE, 2000 The importance of the beta cell in the pathogenesis of type 2 diabetes mellitus. Am J Med 108: Suppl 6a: 2–8.
Lin Z, Zhou J, Li X, et al, 2015 High-normal 2h glucose is associated with defects of insulin secretion and predispose to diabetes in Chinese adults. Endocrine 48: 179–186.
Guillausseau PJ, Meas T, Virally M, Laloi-Michelin M, Médeau V, Kevorkian JP, 2008 Abnormalities in insulin secretion in type 2 diabetes mellitus. Diabetes Metab 34:Suppl 2: 43–48.
Huang S, Czech MP, 2007 The GLUT4 glucose transporter. Cell Metab: 237–252.
Taborsky GJJr, 2010 The physiology of glucagon. J Diabetes Sci Technol 4: 1338–1344.
Lund A, Bagger JI, Christensen M, Knop FK, Vilsboll T, 2014 Glucagon and type 2 diabetes: the return of the alpha cell. Curr Diab Rep 14: 555.
Akter R, Cao P, Noor H, et al, 2016 Islet amyloid polypeptide: structure, function, and pathophysiology. J Diabetes Res 2016: 2798269.
Roth JDI, Hughes H, Kendall E, Baron AD, Anderson CM, 2006 Antiobesity effects of the beta-cell hormone amylin in diet-induced obese rats: effects on food intake, body weight, composition, energy expenditure, and gene expression. Endocrinology 147: 5855–5864.
Deacon CF, Ahren B, 2011 Physiology of incretins in health and disease. Rev Diabet Stud 8: 293–306.
Holst JJ, Knop FK, Vilsbøll T, Kramp T, Madsbad S, 2012 Loss of incretin effect is a specific, important, and early characteristic of type 2 diabetes. Diabetes Care 34:Suppl 2: 251–257.
Gerich J, 2013 Pathogenesis and management of postprandial hyperglycemia: role of incretin-based therapies. Int J Gen Med 6: 877–895.
Drucker DJ, 2006 The biology of incretin hormones. Cell Metab 3: 153–165.
Calanna S, Christensen M, Holst JJ, et al, 2013 Secretion of glucose-dependent insulinotropic polypeptide in patients with type 2 diabetes. Systematic review and meta-analysis of clinical studies. Diabetes Care 36: 3346–3352.
Calanna S, Christensen M, Holst JJ, et al, 2013 Secretion of glucagon-like peptide-1 in patients with type 2 diabetes mellitus: systematic review and meta-analyses of clinical studies. Diabetologia 56: 965–972.
Xu G, Kaneto H, Laybutt DR, Duvivier-Kali VF, Trivedi N, Suzuma K, 2007 Downregulation of GLP-1 and GIP receptor expression by hyperglycemia: possible contribution to impaired incretin effects in diabetes. Diabetes 56: 1551–1558.
Kim W, Egan JM, 2008 The role of incretins in glucose homeostasis and diabetes treatment. Pharmacol Rev 60: 470–512.
Amato A, Baldassano S, Mulè F, 2016 GLP2: an underestimated signal for improving glycaemic control and insulin sensitivity. J Endocrinol 229: R57–66.
Meier JJ, Nauck MA, Pott A, et al, 2006 Glucagon-like peptide 2 stimulates glucagon secretion, enhances lipid absorption, and inhibits gastric acid secretion in humans. Gastroenterology 130: 44–54.
Schmidt WE, Siegel EG, Creutzfeldt W, 1985 Glucagon-like peptide-1 but not glucagon-like peptide-2 stimulates insulin release from isolated rat pancreatic islets. Diabetologia 28: 704–707.
Chan DC, Pang J, Romic G, Watts GF, 2013 Postprandial hypertriglyceridemia and cardiovascular disease: current and future therapies. Curr Atheroscler Rep 15: 309.
Vergès B, 2015 Pathophysiology of diabetic dyslipidaemia: where are we? Diabetologia 58: 886–899.
Ansar S, Koska J, Reaven PD, 2011 Postprandial hyperlipidemia, endothelial dysfunction and cardiovascular risk: focus on incretins. Cardiovasc Diabetol 10: 61.
Kohan AB, 2016 ApoC-III: a potent modulator of hypertriglyceridemia and cardiovascular disease. Curr Opin Endocrinol Diabetes Obes 22: 119–125.
Young SG, Davies BS, Voss CV, et al, 2011 GPIHBP1, an endothelial cell transporter for lipoprotein lipase. J Lipid Res 52: 1869–1884.
Saponaro C, Gaggini M, Carli F, Gastaldelli A, 2015 The subtle balance between lipolysis and lipogenesis: a critical point in metabolic homeostasis. Nutrients 7: 9453–9474.
Parlevliet ET, Wang Y, Geerling JJ, et al, 2012 GLP-1 receptor activation inhibits VLDL production and reverses hepatic steatosis by decreasing hepatic lipogenesis in high-fat-fed APOE*3-Leiden mice. PLoS One 7: e49152.
Hsieh J, Trajcevski KE, Farr SL, et al, 2015 Glucagon-like peptide 2 (GLP-2) stimulates postprandial chylomicron production and postabsorptive release of intestinal triglyceride storage pools via induction of nitric oxide signaling in male hamsters and mice. Endocrinology 156: 3538–3547.
Blackburn P, Lamarche B, Couillard C, et al, 2003 Postprandial hyperlipidemia: another correlate of the “hypertriglyceridemic waist” phenotype in men. Atherosclerosis 171: 327–336.
Couillard C, Bergeron N, Prud’homme D, et al, 1998 Postprandial triglyceride response in visceral obesity in men. Diabetes 47: 953–960.
Choi SH, Ginsberg HN, 2011 Increased very low density lipoprotein secretion, hepatic steatosis and insulin resistance. Trends Endocrinol Metab 22: 353–363.
Blackburn P, Lamarche B, Couillard C, Pascot A, Tremblay A, Bergeron J, 2003 Contribution of visceral adiposity to the exaggerated postprandial lipemia of men with impaired glucose tolerance. Diabetes Care 26: 3303–3309.
Pruneta-Deloche V, Sassolas A, Dallinga-Thie GM, Berthezène F, Ponsin G, Moulin P, 2004 Alteration in lipoprotein lipase activity bound to triglyceride-rich lipoproteins in the postprandial state in type 2 diabetes. J Lipid Res 45: 859–865.
Gaudet D, Brisson D, Tremblay K, et al, 2014 Targeting APOC3 in the familial chylomicronemia syndrome. N Engl J Med 371: 2200–2206.
Gordts PL, Nock R, Son NH, et al, 2016 ApoC-III inhibits clearance of triglyceride-rich lipoproteins through LDL family receptors. J Clin Invest 126: 2855–2866.
Beigneux AP, Davies BS, Gin P, et al, 2007 Glycosylphosphatidylinositol-anchored high-density lipoprotein-binding protein 1 plays a critical role in the lipolytic processing of chylomicrons. Cell Metab 5: 279–291.
Köster A, Chao YB, Mosior M, et al, 2005 Transgenic angiopoietin-like (angptl)4 overexpression and targeted disruption of angptl4 and angptl3: regulation of triglyceride metabolism. Endocrinology 146: 4943–4950.
Foley EM, Gordts PL, Stanford KI, Gonzales JC, Lawrence R, Stoddard N, 2013 Hepatic remnant lipoprotein clearance by heparan sulfate proteoglycans and low-density lipoprotein receptors depend on dietary conditions in mice. Arterioscler Thromb Vasc Biol 33: 2065–2074.
Laatsch A, Merkel M, Talmud PJ, Grewal T, Beisiegel U, Heeren J, 2009 Insulin stimulates hepatic low density lipoprotein receptor-related protein 1 (LRP1) to increase postprandial lipoprotein clearance. Atherosclerosis 204: 105–111.
Ding Y, Xian X, Holland WL, Tsai S, Herz J, 2016 Low-density lipoprotein receptor-related protein-1 protects against hepatic insulin resistance and hepatic steatosis. EBioMedicine 7: 135–145.
Lairon D, Lopez-Miranda J, Williams C, 2007 Methodology for studying postprandial lipid metabolism. Eur J Clin Nutr 61: 1145–1161.
Saydah SH, Miret M, Sung J, Varas C, Gause D, Brancati FL, 2001 Postchallenge hyperglycemia and mortality in a national sample of U.S. adults. Diabetes Care 24: 1397–1402.
Shaw JE, Hodge AM, de Courten M, Chitson P, Zimmet PZ, 1999-Isolated post-challenge hyperglycaemia confirmed as a risk factor for mortality. Diabetologia 42: 1050–1054.
Strojek K, Raz I, Jermendy G, et al, 2016 Factors associated with cardiovascular events in patients with type 2 diabetes and acute myocardial infarction. J Clin Endocrinol Metab 101: 243–253.
Barzin M, Hosseinpanah F, Malboosbaf R, Hajsheikholeslami F, Azizi F, 2013 Isolated post-challenge hyperglycaemia and risk of cardiovascular events: Tehran lipid and glucose study. Diab Vasc Dis Res 10: 324–329.
DECODE Study Group, the European Diabetes Epidemiology Group, 2001 Glucose tolerance and cardiovascular mortality: comparison of fasting and 2-hour diagnostic criteria. Arch Intern Med 161: 397–405.
Cavalot F, Petrelli A, Traversa M, Bonomo K, Fiora E, Conti M, 2006 Postprandial blood glucose is a stronger predictor of cardiovascular events than fasting blood glucose in type 2 diabetes mellitus, particularly in women: lessons from the San Luigi Gonzaga diabetes study. J Clin Endocrinol Metab 91: 813–819.
Brutsaert EF, Shitole S, Biggs ML, et al, 2016 Relations of postload and fasting glucose with incident cardiovascular disease and mortality late in life: The cardiovascular health study. J Gerontol A Biol Sci Med Sci 71: 370–377.
Laurent S, Cockcroft J, Van Bortel L, et al, 2006 Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 27: 2588–2605.
Gordin D, Saraheimo M, Tuomikangas J, et al, 2016 Influence of postprandial hyperglycemic conditions on arterial stiffness in patients with type 2 diabetes. J Clin Endocrinol Metab Jan 101: 1134–1143.
Ando T, Okada S, Niijima Y, et al, 2010 Impaired glucose tolerance, but not impaired fasting glucose, is a risk factor for early-stage atherosclerosis. Diabet Med 27: 1430–1435.
Gong W, Lu B, Yang Z, et al, 2009 Early-stage atherosclerosis in newly diagnosed, untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Metab 35: 458–462.
Mancia G, Fagard R, Narkiewicz K, et al, 2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press 23: 3–16.
Hanefeld M, Koehler C, Schaper F, Fuecker K, Henkel E, Temelkova-Kurktschiev T, 1999 Postprandial plasma glucose is an independent risk factor for increased carotid intima-media thickness in non-diabetic individuals. Atherosclerosis 144: 229–235.
Temelkova-Kurktschiev TS, Koehler C, Henkel E, Leonhardt W, Fuecker K, Hanefeld M, 2000 Postchallenge plasma glucose and glycemic spikes are more strongly associated with atherosclerosis than fasting glucose or HbA1c level. Diabetes Care 23: 1830–1834.
Tanaka K, Kanazawa I, Yamaguchi T, Sugimoto T, 2014 One-hour post-load hyperglycemia by 75g oral glucose tolerance test as a novel risk factor of atherosclerosis. Endoer J 61: 329–334.
Hu Y, Liu W, Huang R, Zhang X, 2010 Postchallenge plasma glucose excursions, carotid intima-media thickness, and risk factors for atherosclerosis in Chinese population with type 2 diabetes. Atherosclerosis 210: 302–306.
Brohall G, Odén A, Fagerberg B, 2006 Carotid artery intima-media thickness in patients with Type 2 diabetes mellitus and impaired glucose tolerance: a systematic review. Diabet Med 23: 609–616.
Shuto Y, Asai A, Nagao M, Sugihara H, Oikawa S, 2015 Repetitive glucose spikes accelerate atherosclerotic lesion formation in C57BL/6 Mice. PLoS One 10: e0136840.
Saely CH, Drexel H, Sourij H, Aczel S, Jahnel H, Zweiker R, 2008 Key role of postchallenge hyperglycemia for the presence and extent of coronary atherosclerosis: an angiographic study. Atherosclerosis 199: 317–322.
Shiraiwa T, Kaneto H, Miyatsuka T, Kato K, Yamamoto K, Kawashima A, 2005 Post-prandial hyperglycemia is an important predictor of the incidence of diabetic microangiopathy in Japanese type 2 diabetic patients. Biochem Biophys Res Commun 336: 339–345.
Shiraiwa T, Kaneto H, Miyatsuka T, et al, 2005 Postprandial hyperglycemia is a better predictor of the progression of diabetic retinopathy than HbA1c in Japanese type 2 diabetic patients. Diabetes Care 28: 2806–2807.
Sartore G, Chilelli NC, Burlina S, Lapolla A, 2013 Association between glucose variability as assessed by continuous glucose monitoring (CGM) and diabetic retinopathy in type 1 and type 2 diabetes. Acta Diabetol 50: 437–442.
Sun ZJ, Yang YC, Wu JS, Wang MC, Chang CL, Lu FH, 2015 Increased risk of glomerular hyperfiltration in subjects with impaired glucose tolerance and newly diagnosed diabetes. Nephrol Dial Transplant 31: 1295–1301.
Lorenzo C, Hartnett S, Hanley AJ, Rewers MJ, Wagenknecht LE, Karter AJ, 2013 Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study. J Clin Endocrinol Metab 98: 1622–1630.
Monnier L, Lapinski H, Colette C, 2003 Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c). Diabetes Care 26: 881–885.
Woerle HJ, Neumann C, Zschau S, et al, 2007 Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract 77: 280–285.
Schernthaner G, Guerci B, Gallwitz B, et al, 2010 Impact of postprandial and fasting glucose concentrations on HbA1c in patients with type 2 diabetes. Diabetes Metab 36: 389–394.
Stensvold I, Tverdal A, Urdal P, Graff-Iversen S, 1993 Non-fasting serum triglyceride concentration and mortality from coronary heart disease and any cause in middle aged Norwegian women. BMJ 307: 1318–1322.
Bansal S, Buring JE, Rifai N, Mora S, Sacks FM, Ridker PM, 2007 Fasting compared with nonfasting triglycerides and risk of cardiovascular events in women. JAMA 298: 309–316.
Stampfer MJ, Krauss RM, Ma J, Blanche PJ, Holl LG, Sacks FM. 1996 A prospective study of triglyceride level, low-density lipoprotein particle diameter, and risk of myocardial infarction. JAMA 276: 882–888.
Nordestgaard BG, Benn M, Schnohr P, Tybjaerg-Hansen A, 2007 Nonfasting triglycerides and risk of myocardial infarction, ischemic heart disease, and death in men and women JAMA 298: 299–308.
Nordestgaard BG, Freiberg JJ, 2011 Clinical relevance of non-fasting and postprandial hypertriglyceridemia and remnant cholesterol. Curr Vasc Pharmacol 9: 281–286.
Teno S, Uto Y, Nagashima H, et al, 2000 Association of postprandial hypertriglyceridemia and carotid intimamedia thickness in patients with type 2 diabetes. Diabetes Care 23: 1401–1406.
Mori Y, Itoh Y, Komiya H, Tajima N, 2005 Association between postprandial remnant-like particle triglyceride (RLP-TG) levels and carotid intima-media thickness (IMT) in Japanese patients with type 2 diabetes: assessment by meal tolerance tests (MTT). Endocrine 28: 157–163.
Ahmad J, Hameed B, Das G, Siddiqui MA, Ahmad I, 2005 Postprandial hypertriglyceridemia and carotid intima-media thickness in north Indian type 2 diabetic subjects. Diabetes Res Clin Pract 69: 142–150.
Chen X, Tian H, Liu R, 2003 Association between fasting and postprandial triglyceride levels and carotid intima-media thickness in type 2 diabetes patients. Chin Med J (Engl) 116: 1933–1935.
Daskalova DC, Kolovou GD, Panagiotakos DB, Pilatis ND, Cokkinos DV, 2005 Increase in aortic pulse wave velocity is associated with abnormal postprandial triglyceride response. Clin Cardiol 28: 577–583.
Bureau C, Laurent J, Robic MA, et al, 2016 Central obesity is associated with non-cirrhotic portal vein thrombosis. J Hepatol 64: 427–432.
Papoutsakis C, Chondronikola M, Antonogeorgos G, et al, 2015 Associations between central obesity and asthma in children and adolescents: a case-control study. J Asthma 52: 128–134.
Capelo AV, De Fonseca VM, Peixoto MV, De Carvalho SR, Guerino LG, 2015 Central obesity and other factors associated with uncontrolled asthma in women. Allergy Asthma Clin Immunol 11: 12.
Pang Q, Zhang JY, Song SD, et al, 2015 Central obesity and nonalcoholic fatty liver disease risk after adjusting for body mass index. World J Gastroenterol 21: 1650–1662.
Beydoun MA, Beydoun HA, Wang Y, 2008 Obesity and central obesity as risk factors for incident dementia and its subtypes: a systematic review and meta-analysis. Obes Rev 9: 204–218.
Oka R, Kobayashi J, Miura K, Nagasawa S, Moriuchi T, Hifumi S, 2009 Difference between fasting and nonfasting triglyceridemia; the influence of waist circumference. J Atheroscler Thromb 16: 633–640.
Lacroix S, Rosiers CD, Tardif JC, Nigam A, 2012 The role of oxidative stress in postprandial endothelial dysfunction. Nutr Res Rev 25: 288–301.
Ceriello A, Taboga C, Tonutti L, et al, 2002 Evidence for an independent and cumulative effect of postprandial hypertriglyceridemia and hyperglycemia on endothelial dysfunction and oxidative stress generation: effects of short- and long-term simvastatin treatment. Circulation 106: 1211–1218.
Lee IK, Kim HS, Bae JH, 2002 Endothelial dysfunction: its relationship with acute hyperglycaemia and hyperlipidemia. Int J Clin Pract Suppl 129: 59–64.
Esposito K, Nappo F, Marfella R, et al, 2002 Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation 106: 2067–2072.
Nappo F, Esposito K, Cioffi M, et al, 2002 Postprandial endothelial activation in healthy subjects and in type 2 diabetic patients: Role of fat and carbohydrate meal. J Am Coll Cardiol 39: 1145–1150.
Ceriello A, Quagliaro L, Piconi L, et al, 2004 Effect of postprandial hypertriglyceridemia and hyperglycemia on circulating adhesion molecules and oxidative stress generation and the possible role of simvastatin treatment. Diabetes 53: 701–710.
Ridker PM, Hennekens CH, Roitman-Johnson B, Stampfer MJ, Allen J, 1998 Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351: 88–92.
Morisaki N, Saito I, Tamura K, et al, 1997 New indices of ischemic heart disease and aging: studies on the serum levels of soluble intercellular adhesion molecule-1 (ICAM-1) and soluble vascular cell adhesion molecule-1 (VCAM-1) in patients with hypercholesterolemia and ischemic heart disease. Atherosclerosis 131: 43–48.
Peter K, Nawroth P, Conradt C, et al, 1997 Circulating vascular cell adhesion molecule-1 correlates with the extent of human atherosclerosis in contrast to circulating intercellular adhesion molecule-1, E-selectin, P-selectin, and thrombomodulin. Arterioscler Thromb Vasc Biol 17: 505–512.
Motojima K, Azuma K, Kitahara Y, et al, 2008 Repetitive postprandial hypertriglyceridemia induces monocyte adhesion to aortic endothelial cells in Goto-Kakizaki rats. Endocr J 55: 373–379.
de Vries MA, Alipour A, Klop B, et al, 2015 Glucose-dependent leukocyte activation in patients with type 2 diabetes mellitus, familial combined hyperlipidemia and healthy controls. Metabolism 64: 213–217.
Santilli F, Formoso G, Sbraccia P, et al, 2010 Postprandial hyperglycemia is a determinant of platelet activation in early type 2 diabetes mellitus. J Thromb Haemost 8: 828–387.
Gresele P, Guglielmini G, De Angelis M, et al, 2003 Acute, short-term hyperglycemia enhances shear stress-induced platelet activation in patients with type II diabetes mellitus. J Am Coll Cardiol 41: 1013–1020.
Byrne CD, Wareham NJ, Martensz ND, Humphries SE, Metcalfe JC, Grainger DJ, 1998 Increased PAI activity and PAI-1 antigen occurring with an oral fat load: associations with PAI-1 genotype and plasma active TGF-beta levels. Atherosclerosis 140: 45–53.
Tholstrup T, Miller GJ, Bysted A, Sandström B, 2003 Effect of individual dietary fatty acids on postprandial activation of blood coagulation factor VII and fibrinolysis in healthy young men. Am J Clin Nutr 77: 1125–1132.
Coles N, Bremer K, Kives S, Zhao X, Hamilton J, 2016 Utility of the Oral Glucose Tolerance Test to Assess Glucose Abnormalities in Adolescents with Polycystic Ovary Syndrome. J Pediatr Adolesc Gynecol 29: 48–52.
Kyaw Tun T, McGowan A, Phelan N, et al, 2016 Obesity and insulin resistance are the main determinants of postprandial lipoprotein dysmetabolism in polycystic ovary syndrome. Int J Endocrinol 2016: 9545239.
Bahceci M, Aydemir M, Tuzcu A, 2007 Effects of oral fat and glucose tolerance test on serum lipid profile, apolipoprotein, and CRP concentration, and insulin resistance in patients with polycystic ovary syndrome. Fertil Steril 87: 1363–1368.
Diamanti-Kandarakis E, Xyrafis X, Boutzios G, Christakou C, 2008 Pancreatic beta-cells dysfunction in polycystic ovary syndrome. Panminerva Med 50: 315–325.
Economou F, Xyrafis X, Livadas S, et al, 2009 In overweight/obese but not in normal-weight women, polycystic ovary syndrome is associated with elevated liver enzymes compared to controls. Hormones (Athens) 8: 199–206.
Kimura Y, Hyogo H, Ishitobi T, Nabeshima Y, Arihiro K, Chayama K, 2011 Postprandial insulin secretion pattern is associated with histological severity in non-alcoholic fatty liver disease patients without prior known diabetes mellitus. J Gastroenterol Hepatol 26: 517–522.
Manchanayake J, Chitturi S, Nolan C, Farrell GC, 2011 Postprandial hyperinsulinemia is universal in non-diabetic patients with nonalcoholic fatty liver disease. J Gastroenterol Hepatol 26: 510–516.
Musso G, Gambino R, De Michieli F, et al, 2008 Association of liver disease with postprandial large intestinal triglyceride-rich lipoprotein accumulation and pro/antioxidant imbalance in normolipidemic non-alcoholic steatohepatitis. Ann Med 40: 383–394.
Matikainen N, Taskinen MR, Stennabb S, et al, 2012 Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceriderich lipoproteins and liver fat. Eur J Endocrinol 166: 487–492.
American Diabetes Association, 2016 Standards of medical care in diabetes. Diabetes Care 38: 1–94.
International Diabetes Federation Guideline Development Group, 2014 Guideline for management of postmeal glucose in diabetes. Diabetes Res Clin Pract 103: 256–268.
Stettier C, Stahl M, Allemann S, et al, 2008 Association of 1,5-anhydroglucitol and 2-h postprandial blood glucose in type 2 diabetic patients. Diabetes Care 31: 1534–1535.
Seok H, Huh JH, Kim HM, et al, 2015 1,5-anhydroglucitol as a useful marker for assessing short-term glycemic excursions in type 1 diabetes. Diabetes Metab J 39: 164–170.
Berglund L, Brunzell JD, Goldberg AC, et al, 2012 Evaluation and treatment of hypertriglyceridemia: an Endocrine Society clinical practice guideline. J Clin Endocrinol Metab 97: 2969–2989.
Jellinger PS, Smith DA, Mehta AE, et al, AACE Task Force for Management of Dyslipidemia and Prevention of Atherosclerosis, 2012 American Association of Clinical Endocrinologists’ Guidelines for Management of Dyslipidemia and Prevention of Atherosclerosis: Executive summary. Endocr Pract 18: 269–293.
Su JW, Nzekwu MM, Cabezas MC, et al, 2009 Methods to assess impaired post-prandial metabolism and the impact for early detection of cardiovascular disease risk. Eur J Clin Invest 39: 741–754.
Nagata T, Sugiyama D, Kise T, et al, 2012 Fasting remnant lipoproteins can predict postprandial hyperlipidemia. Lipids Health Dis 11: 146.
White KT, Moorthy MV, Akinkuolie AO, et al, 2015 Identifying an optimal cutpoint for the diagnosis of hypertriglyceridemia in the nonfasting state. Clin Chem 61: 1156–1163.
Canadian Diabetes Association Clinical Practice Guidelines Expert Committee, 2013 Targets for glycemic control. Can J Diabetes 37 Suppl 1: 31–34.
Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC); European Association for the Study of Diabetes (EASD), Rydén L, Grant PJ, Anker SD, et al, 2014 ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD — summary. Diab Vasc Dis Res 11: 133–173.
O’Keefe JH, Gheewala NM, O’Keefe JO, 2008 Dietary strategies for improving post-prandial glucose, lipids, inflammation, and cardiovascular health. J Am Coll Cardiol 51: 249–255.
Hollekim-Strand SM, Malmo V, Follestad T, Wisløff U, Ingul CB, 2015 Fast food increases postprandial cardiac workload in type 2 diabetes independent of pre-exercise: A pilot study. Nutr J 14: 79.
De Natale C, Annuzzi G, Bozzetto L, et al, 2009 Effects of a plant-based high-carbohydrate/high-fiber diet versus high-monounsaturated fat/low-carbohydrate diet on postprandial lipids in type 2 diabetic patients. Diabetes Care 32: 2168–2173.
Giacco R, Costabile G, Delia Pepa G, et al, 2014 A whole-grain cereal-based diet lowers postprandial plasma insulin and triglyceride levels in individuals with metabolic syndrome. Nutr Metab Cardiovasc Dis 24: 837–844.
Dandona P, Ghanim H, Abuaysheh S, et al, 2015 Decreased insulin secretion and incretin concentrations and increased glucagon concentrations after a high-fat meal when compared with a high-fruit and -fiber meal. Am J Physiol Endocrinol Metab 308: E185–191.
Rizkalla SW, Taghrid L, Laromiguiere M, et al, 2004 Improved plasma glucose control, whole-body glucose utilization, and lipid profile on a low-glycemic index diet in type 2 diabetic men: a randomized controlled trial. Diabetes Care 27: 1866–1872.
Monro JA, Shaw M, 2008 Glycemic impact, glycemic glucose equivalents, glycemic index, and glycemic load: definitions, distinctions, and implications. Am J Clin Nutr 87: Suppl: 237–243.
Jenkins DJ, Wolever TM, Taylor RH, et al, 1981 Glycemic index of foods: a physiologie al basis for carbohydrate exchange. Am J Clin Nutr 34: 362–366.
Kang X, Wang C, Lifang L, et al, 2013 Effects of different proportion of carbohydrate in breakfast on postprandial glucose excursion in normal glucose tolerance and impaired glucose regulation subjects. Diabetes Technol Ther 15: 569–574.
Miyoshi T, Noda Y, Ohno, et al, 2014 Omega-3 fatty acids improve postprandial lipemia and associated endothelial dysfunction in healthy individuals — a randomized cross-over trial. Biomed Pharmacother 68: 1071–1077.
Wong AT, Chan DC, Barrett PH, Adams LA, Watts GF, 2014 Effect of ω-3 fatty acid ethyl esters on apolipoprotein B-48 kinetics in obese subjects on a weight-loss diet: a new tracer kinetic study in the postprandial state. J Clin Endocrinol Metab 99: E1427–1435.
Hedengran A, Szecsi PB, Dyerberg J, Harris WS, Stender S, 2015 n-3 PUFA esterified to glycerol or as ethyl esters reduce non-fasting plasma triacylglycerol in subjects with hypertriglyceridemia: a randomized trial. Lipids 50: 165–175.
Park YM, Heden TD, Liu Y, et al, 2015 A high-protein breakfast induces greater insulin and glucose-dependent insulinotropic peptide responses to a subsequent lunch meal in individuals with type 2 diabetes. J Nutr 145: 452–458.
Mamo JC, James AP, Soares MJ, Griffiths DG, Purcell K, Schwenke JL, 2005 A low-protein diet exacerbates postprandial chylomicron concentration in moderately dyslipidaemic subjects in comparison to a lean red meat protein-enriched diet. Eur J Clin Nutr 59: 1142–1148.
MacLeod SF, Terada T, Chahal BS, Boulé NG, 2013 Exercise lowers postprandial glucose but not fasting glucose in type 2 diabetes: a meta-analysis of studies using continuous glucose monitoring. Diabetes Metab Res Rev 29: 593–603.
Mitchell JB, Rowe JR, Shah M, Barbee JJ, Watkins AM, Stephens C, 2008 Effect of prior exercise on postprandial triglycerides in overweight young women after ingesting a high-carbohydrate meal. Int J Sport Nutr Exerc Metab 18: 49–65.
Zhang JQ, Ji LL, Fogt DL, Fretwell VS, 1985 Effect of exercise duration on postprandial hypertriglyceridemia in men with metabolic syndrome. J Appl Physiol 103: 1339–1345.
Tobin LW, Kiens B, Galbo H, 2008 The effect of exercise on postprandial lipidemia in type 2 diabetic patients. Eur J Appl Physiol 102: 361–370.
Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JW, 2014 The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg 260: 984–992.
Baskota A, Li S, Dhakal N, Liu G, Tian H, 2015 Bariatric surgery for type 2 diabetes mellitus in patients with BMI <30 kg/m2: A systematic review and meta-analysis. PLoS One 10: e0132335.
DiNicolantonio JJ, Bhutani J, O’Keefe JH, 2015 Acarbose: safe and effective for lowering postprandial hyperglycaemia and improving cardiovascular outcomes. Open Heart 2: e000327.
Kato T, Node K, 2014 Therapeutic potential of α-glucosidase inhibitors to prevent postprandial endothelial dysfunction. Int Heart J 55: 386–390.
Aleskow Stein S, Lamos EM, Davis SN, 2012 Areview of the efficacy and safety of oral antidiabetic drugs. Expert Opin Drug Saf 12: 153–175.
Rosenstock J, Hassman DR, Madder RD, et al, 2004 Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. Diabetes Care 27: 1265–1270.
Esposito K, Giugliano D, Nappo F, Marfella R; Campanian Postprandial Hyperglycemia Study Group, 2004 Regression of carotid atherosclerosis by control of postprandial hyperglycemia in type 2 diabetes mellitus. Circulation 110: 214–219.
Werner U, 2014 Effects of the GLP1 receptor agonist lixisenatide on postprandial glucose and gastric emptying-preclinical evidence. J Diabetes Complications 28: 110–114.
Cervera AI, Wajcberg E, Sriwijitkamol A, et al, 2008 Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab 294: E846–852.
Pfeffer MA, Claggett B, Diaz R, et al, 2015 Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med 373: 2247–2257.
Marso SP, Daniels GH, Brown-Frandsen K, et al, 2016 Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med 375: 311–322.
Godinho R, Mega C, Teixeira-de-Lemos E, et al, 2015 The place of dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapeutics: A «me too» or «the special one» antidiabetic class? J Diabetes Res 2015: 806979.
Tanimoto M, Kanazawa A, Hirose T, et al, 2015 Comparison of sitagliptin with nateglinide on postprandial glucose and related hormones in drug-naïve Japanese patients with type 2 diabetes mellitus: A pilot study. J Diabetes Investig 6: 560–566.
Ryan G, Briscoe TA, Jobe, 2009 Review of pramlintide as adjunctive therapy in treatment of type 1 and type 2 diabetes. Drug Des Devel Ther 2: 203–214.
European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al, 2011 ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J 32: 1769–1818.
Kolovou GD, Anagnostopoulou KK, Salpea KD, Daskalopoulou SS, Mikhailidis DP. 2007 The effect of statins on postprandial lipemia. Curr Drug Targets 8: 551–560.
Parhofer KG, Laubach E, Barrett PH, 2003 Effect of atorvastatin on postprandial lipoprotein metabolism in hypertriglyceridemic patients. J Lipid Res 44: 1192–1198.
Arao K, Yasu T, Umemoto T, et al, 2009 Effects of pravastatin on fasting and postprandial endothelial function and blood rheology in patients with stable coronary artery disease. Circ J 73: 1523–1530.
Nagashima H, Endo M, 2011 Pravastatin prevents postprandial endothelial dysfunction via reduction of the serum triglyceride level in obese male subjects. Heart Vessels 26: 428–434.
Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, Visseren FL, 2009 The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients. Atherosclerosis 202: 216–224.
Kikuchi K, Nezu U, Inazumi K, et al, 2012 Double-blind randomized clinical trial of the effects of ezetimibe on postprandial hyperlipidaemia and hyperglycaemia. J Atheroscler Thromb 19: 1093–1101.
Hiramitsu S, Miyagishima K, Ishii J, et al, 2012 Effect of ezetimibe on lipid and glucose metabolism after a fat and glucose load. J Cardiol 60: 395–400.
Bozzetto L, Annuzzi G, Corte GD, et al, 2011 Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes. Atherosclerosis 217: 142–148.
Yunoki K, Nakamura K, Miyoshi T, et al, 2011 Ezetimibe improves postprandial hyperlipemia and its induced endothelial dysfunction. Atherosclerosis 217: 486–491.
Westerink J, Deanfield JE, Imholz BP, et al, 2013 High-dose statin monotherapy versus low-dose statin/ezetimibe combination on fasting and postprandial lipids and endothelial function in obese patients with the metabolic syndrome: The PANACEA study. Atherosclerosis 227: 118–124.
Kolovou GD, Kostakou PM, Anagnostopoulou KK, Cokkinos DV, 2008 Therapeutic effects of fibrates in postprandial lipemia. Am J Cardiovasc Drugs 8: 243–255.
Rosenson RS, Wolff DA, Huskin AL, Helenowski IB, Rademaker AW, 2007 Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome. Diabetes Care 30: 1945–1951.
Sharifi F, Hojeghani N, Mazloomzadeh S, Shajari Z, 2013 The efficacy of ezetimibe added to ongoing fibrate-statin therapy on postprandial lipid profile in the patients with type 2 diabetes mellitus. J Diabetes Metab Disord 12: 24.
The ACCORD Study Group, 2010 Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med 362: 1563–1574.
Reyes-Soffer G, Ngai CI, Lovato L, et al, 2013 Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial. Diabetes Care 36: 422–428.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Pappas, C., Kandaraki, E.A., Tsirona, S. et al. Postprandial dysmetabolism: Too early or too late?. Hormones 15, 321–344 (2016). https://doi.org/10.14310/horm.2002.1697
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.14310/horm.2002.1697